&nbsp;

PCC_4233_FN_CancerScreeningGuide.pdf

Nov 2021

Document

PCC_4233_FN_CancerScreeningGuide_FR.pdf

Nov 2021

Regimen

PEMB(MNT)

Cancer Type:

Gynecologic,

Cervix

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - Metastatic, Persistent, or Recurrent Carcinoma of the Cervix

Drugs Used:

pembrolizumab

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

PEMB

Cancer Type:

Gynecologic,

Endometrial

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - Previously Treated MSI-H/dMMR Advanced Endometrial Cancer

Drugs Used:

pembrolizumab

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

PEMB

Cancer Type:

Breast

Intent: Adjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used:

pembrolizumab

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

PACL+PERTRAS(SC)

Cancer Type:

Breast

Intent: Palliative

Drugs Used:

PERTuzumab / trastuzumab (subcut) (Unfunded),

PACLitaxel

Quick Link(s):

Regimen Monograph

May 2022

Regimen

PACL(W)+PERTRAS(SC)

Cancer Type:

Breast

Intent: Palliative

Drugs Used:

PERTuzumab / trastuzumab (subcut) (Unfunded),

PACLitaxel

Quick Link(s):

Regimen Monograph

May 2022

Regimen

PERTRAS(SC)

Cancer Type:

Breast

Intent: Palliative

Drugs Used:

PERTuzumab / trastuzumab (subcut) (Unfunded)

Quick Link(s):

Regimen Monograph

May 2022

Regimen

PEMI

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Drugs Used:

pemigatinib (Unfunded)

Quick Link(s):

Regimen Monograph

Jun 2022

Statistical Reports

Key Findings [2022]

Document

PanCanadianReviewProcess.png

Nov 2022

Document